Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity

Clinical Cancer Research

Volumn 18, Issue 14, 2012, Pages 3834-3845

  Loo, Deryk ^a   Alderson, Ralph F ^a   Chen, Francine Z ^a   Huang, Ling ^a   Zhang, Wenjun ^a   Gorlatov, Sergey ^a   Burke, Steve ^a   Ciccarone, Valentina ^a   Li, Hua ^a   Yang, Yinhua ^a   Son, Tom ^a   Chen, Yan ^a   Easton, Ann N ^a   Li, Jonathan C ^a   Rillema, Jill R ^a   Licea, Monica ^a   Fieger, Claudia ^a   Liang, Tony W ^a   Mather, Jennie P ^a   Koenig, Scott ^a   Stewart, Stanford J ^a   Johnson, Syd ^a   Bonvini, Ezio ^a   Moore, Paul A ^a   more..

^a Analytical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16A ANTIGEN; CD276 ANTIGEN; FC RECEPTOR IIB; LYMPHOCYTE ANTIGEN; MGA 271; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY ENGINEERING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; HAPLORHINI; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; KIDNEY CARCINOMA; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPEATED DRUG DOSE; SINGLE DRUG DOSE; STEM CELL; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; B7 ANTIGENS; CELL LINE, TUMOR; EPITOPES; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NEOPLASMS;

EID: 84863928141     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0715     Document Type: Article

References (37)

1. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-48. (Pubitemid 29415219)
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
3. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914-21. (Pubitemid 46630920)
4. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8. (Pubitemid 34525533)
5. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7. (Pubitemid 46606207)
6. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26: 1789-96.
7. Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, et al. Impact of Fcgamma RIIa-FcgammaRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009;27:1122-9.
8. Loo DT, Mather JP. Antibody-based identification of cell surface antigens: targets for cancer therapy. Curr Opin Pharmacol 2008;8: 627-31.
9. Roberts PE. Isolation and establishment of human tumor stem cells. Methods Cell Biol 2008;86:325-42.
10. Loo D, Pryer N, Young P, Liang T, Coberly S, King KL, et al. The glycotope-specific RAV12 monoclonal antibody induces oncosis in vitro and has antitumor activity against gastrointestinal adenocarcinoma tumor xenografts in vivo. Mol Cancer Ther 2007;6:856-65. (Pubitemid 46554555)
11. Zang X, Allison JP. The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 2007;13:5271-9. (Pubitemid 47510350)
12. Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors. Cancer Res 2007;67:8882-90. (Pubitemid 47437465)
13. Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti- HER2 monoclonal antibody with enhanced Fc-gamma receptor binding properties. Breast Cancer Res 2011;13:R123.
14. Syd Johnson, Bhaswati Barat, Paul Moore, Ezio Bonvini. Novel applications of bispecific DART proteins. In:Schmidt S, editor. Fusion protein technologies for biopharmaceuticals: Applications and Challenges. New Jersey: Wiley-Blackwell; 2012.
15. Zang X, Thompson RH, Al-Ahmadie HA, SerioAM, Reuter VE, Eastham JA, et al. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc Natl Acad Sci U S A 2007;104:19458-63.
16. Chavin G, Sheinin Y, Crispen PL, Boorjian SA, Roth TJ, Rangel L, et al. Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res 2009;15: 2174-80.
17. Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, et al. B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res 2007;67: 7893-900. (Pubitemid 47281385)
18. Crispen PL, Sheinin Y, Roth TJ, Lohse CM, Kuntz SM, Frigola X, et al. Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res 2008;14:5150-7.
19. Loos M, Hedderich DM, Ottenhausen M, Giese NA, Laschinger M, Esposito I, et al. Expression of the costimulatory molecule B7-H3 is associated with prolonged survival in human pancreatic cancer. BMC Cancer 2009;9:463.
20. Yamato I, Sho M, Nomi T, Akahori T, Shimada K, Hotta K, et al. Clinical importance of B7-H3 expression in human pancreatic cancer. Br J Cancer 2009;101:1709-16.
21. Sun J, Chen LJ, Zhang GB, Jiang JT, Zhu M, Tan Y, et al. Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother 2010;59: 1163-71.
22. Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer 2006;53:143-51. (Pubitemid 43994236)
23. Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod Pathol 2010;23:1104-12.
24. Boorjian SA, Sheinin Y, Crispen PL, Farmer SA, Lohse CM, Kuntz SM, et al. T-Cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 2008;14:4800-7.
25. Modak S, Kramer K, Gultekin SH, Guo HF, Cheung NK. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res 2001;61: 4048-54. (Pubitemid 32720969)
26. Hofmeyer KA, Ray A, Zang X. The contrasting role of B7-H3. Proc Natl Acad Sci U S A 2008;105:10277-8.
27. Chapoval AI, Ni J, Lau JS, Wilcox RA, Flies DB, Liu D, et al. B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. Nat Immunol 2001;2:269-74. (Pubitemid 33706005)
28. Seeger RC, Rosenblatt HM, Imai K, Ferrone S. Common antigenic determinants on human melanoma, glioma, neuroblastoma, and sarcoma cells defined with monoclonal antibodies. Cancer Res 1981;41: 2714-7. (Pubitemid 11071801)
29. Chen YW, Tekle C, Fodstad O. The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion. Curr Cancer Drug Targets 2008;8: 404-13.
30. Natali PG, Giacomini P, Bigotti A, Imai K, Nicotra MR, Ng AK, et al. Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res 1983;43:660-8. (Pubitemid 13193863)
31. Xu H, Cheung IY, Guo HF, Cheung NK. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res 2009;69:6275-81.
32. Castriconi R, Dondero A, Augugliaro R, Cantoni C, Carnemolla B, Sementa AR, et al. Identification of 4Ig-B7-H3 as a neuroblastomaassociated molecule that exerts a protective role from an NK cellmediated lysis. Proc Natl Acad Sci U S A 2004;101:12640-5. (Pubitemid 39122076)
33. Leitner J, Klauser C, Pickl WF, Stockl J, Majdic O, Bardet AF, et al. B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur J Immunol 2009;39:1754-64.
34. Suh WK, Gajewska BU, Okada H, Gronski MA, BertramEM, Dawicki W, et al. The B7 family member B7-H3 preferentially down-regulates T helper type 1-mediated immune responses. Nat Immunol 2003;4: 899-906. (Pubitemid 37098661)
35. Liu H, Tekle C, Chen YW, Kristian A, Zhao Y, Zhou M, et al. B7-h3 silencing increases paclitaxel sensitivity by abrogating jak2/stat3 phosphorylation. Mol Cancer Ther 2011;10:960-71.
36. Yuan H, Wei X, Zhang G, Li C, Zhang X, Hou J. B7-H3 Over expression in prostate cancer promotes tumor cell progression. J Urol 2011;186: 1093-9.
37. Pan Z, Hooley J, Smith DH, Young P, Roberts PE, Mather JP. Establishment of human ovarian serous carcinomas cell lines in serum free media. In:Al-Rubeai, editor. Methods. New York: Elsevier Press; 2012.